In retrospect, it all went wrong for Bioasis Technologies when the merger with Midatech Pharma fell through in January. Now, the biotech is suspending operations and counting down the last days before its creditors call in over $4 million in loans.
NEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the œCompany or œBioasis), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Provides Update on Business Operations
Bioasis Announces AGM Results and Provides Update on Financial Position
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders
Midatech Pharma has identified a path past its cash crunch. With its runway set to end in March, the drug delivery specialist has secured financing and struck a deal to buy Bioasis Technologies to transition into a rare disease biotech.
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
Bioasis Technologies Inc. Announces Shareholder Webinar